Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide Prevents Apolipoprotein B-Containing Lipoprotein Oxidation, Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Letelier, Nicole
  • Farré, Núria|||0000-0003-3110-6572
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Nieto-Nicolau, Núria|||0000-0002-3527-0110
  • Rodríguez-Millán, Elisabeth
  • Santos, David|||0000-0003-1157-4969
  • Pallarès, Victor|||0000-0002-9851-0345
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Vázquez del Olmo, Tania
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Casaroli-Marano, Ricardo Pedro|||0000-0003-1812-9323
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
The potential of nicotinamide (NAM) to prevent atherosclerosis has not yet been examined. This study investigated the effect of NAM supplementation on the development of atherosclerosis in a mouse model of the disease. The development of aortic atherosclerosis was significantly reduced (NAM low dose: 45%; NAM high dose: 55%) in NAM-treated, apolipoprotein (Apo)E-deficient mice challenged with a Western diet for 4 weeks. NAM administration significantly increased (1.8-fold) the plasma concentration of proatherogenic ApoB-containing lipoproteins in NAM high-dose (HD)-treated mice compared with untreated mice. However, isolated ApoB-containing lipoproteins from NAM HD mice were less prone to oxidation than those of untreated mice. This result was consistent with the decreased (1.5-fold) concentration of oxidized low-density lipoproteins in this group. Immunohistochemical staining of aortas from NAM-treated mice showed significantly increased levels of IL-10 (NAM low-dose (LD): 1.3-fold; NAM HD: 1.2-fold), concomitant with a significant decrease in the relative expression of TNFα (NAM LD: -44%; NAM HD: -57%). An improved anti-inflammatory pattern was reproduced in macrophages cultured in the presence of NAM. Thus, dietary NAM supplementation in ApoE-deficient mice prevented the development of atherosclerosis and improved protection against ApoB-containing lipoprotein oxidation and aortic inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Pérez, Antonio|||0000-0001-5528-1143
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Canyelles, Marina|||0000-0002-0278-5337
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

  • Canyelles, Marina|||0000-0002-0278-5337
  • Plaza, Melania|||0000-0002-1471-3672
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Llobet, Dolors
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mojal, Sergi|||0000-0003-0523-3869
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Souto, Juan Carlos|||0000-0003-2092-5142
Background: The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. Methods: The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. Results: No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. Conclusions: No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Hernández García, Marta|||0000-0003-1237-298X
  • Ortega, Emilio|||0000-0002-2217-8905
  • Amigó, Núria|||0000-0002-0116-9145
  • Real, J.
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Miñambres, Inka|||0000-0002-0899-3938
  • López, C.
  • Lecube, Albert|||0000-0001-9684-0183
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
Aims: The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined. Methods: We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7.0%). Results: Advanced lipoprotein analysis revealed a significant reduction from baseline in serum concentrations of triglycerides (TG), cholesterol (C), and apolipoprotein (Apo)B-containing lipoproteins of treated subjects (VLDL-TG: -21%, IDL-TG: -30%, LDL-TG: -34%, LDL-TG: -36%, P < 0.05; VLDL-C: -23%, IDL-C: -44%, LDL-C: -16%; p < 0.05). Decreased VLDL and LDL lipids were mainly attributed to concomitant reductions in the concentration of medium-sized VLDL (-36%) and medium-sized LDL (-31%) and, to a lesser extent, to large-sized LDL (-14%). Notably, proatherogenic IDL characteristics and related surrogates of atherogenicity were resolved upon achievement of optimal glycemic status. Moreover, the concentration of HDL-TG was also reduced (-18%) at follow-up. Conclusions: Our data showed that the achievement of optimal glycemic control after T1D onset corrected hidden derangements in ApoB-containing lipoproteins (particularly IDL) and HDL-TG that are related to higher cardiovascular risk in poorly controlled T1D.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases

  • Rotllan, Noemi|||0000-0002-0587-8045
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Canyelles, Marina|||0000-0002-0278-5337
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Benitez, Sonia|||0000-0003-3565-0743
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic stress directly impact the cardiovascular system. Over the last few years, the contributions of altered nicotinamide adenine dinucleotide (NAD+) metabolism to aging and other pathological conditions closely related to cardiovascular diseases have been intensively investigated. NAD+ bioavailability decreases with age and cardiometabolic conditions in several mammalian tissues. Compelling data suggest that declining tissue NAD+ is commonly related to mitochondrial dysfunction and might be considered as a therapeutic target. Thus, NAD+ replenishment by either genetic or natural dietary NAD+-increasing strategies has been recently demonstrated to be effective for improving the pathophysiology of cardiac and vascular health in different experimental models, as well as human health, to a lesser extent. Here, we review and discuss recent experimental evidence illustrating that increasing NAD+ bioavailability, particularly by the use of natural NAD+ precursors, may offer hope for new therapeutic strategies to prevent and treat cardiovascular diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advanced quantitative lipoprotein characteristics do not relate to healthy dietary patterns in adults from a mediterranean area

  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Real, Jordi|||0000-0002-5979-8948
  • Hernández García, Marta|||0000-0003-1237-298X
  • Falguera, Mireia|||0000-0002-7846-8952
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Mauricio, Didac|||0000-0002-2868-0250
We aimed to assess the potential relationship between dietary patterns (i.e., Mediterranean diet and healthy eating) and the advanced lipoprotein profile (ALP) in a representative cohort of the Mediterranean population. Thus, ALP data from 1142 participants, including 222 with type 1 (19.4%) and 252 type 2 diabetes (22.1%), and 668 subjects without diabetes were used to study cross-sectional associations between quantitative characteristics of lipoproteins and adherence to the Mediterranean diet. The alternate Mediterranean diet score (aMED) and the alternate healthy eating index (aHEI) were calculated. The ALP was determined by nuclear magnetic resonance (NMR) spectrometry. Bivariable and multivariable analyses were performed. Participants in the third tertile of the aMED showed higher levels of low-density lipoprotein triglycerides (LDL-TG) (mean (SD) 17.5 (5.0); p = 0.037), large high-density lipoprotein particles (HDL-P) (0.3 (0.1); p = 0.037), and medium low-density lipoprotein particles (LDL-P) (434.0 (143.0); p = 0.037). In comparison with participants in the second and first tertiles of the aHEI, participants in the third tertile had higher levels of LDL-TG (17.7 (5.0); p = 0.010), and large HDL-P (0.3 (0.1); p = 0.002), IDL-C (11.8 (5.0); p = 0.001), intermediate-density lipoprotein triglycerides (IDL-TG) (13.2 (4.2); p < 0.001), LDL-TG (17.7(5.0); p = 0.010), high-density lipoprotein triglycerides (HDL-TG) (14.5 (4.4); p = 0.029,) large HDL-P (0.3 (0.1); p = 0.002) and very-low-density lipoprotein particles (VLDL-P) size (42.1 (0.2); p = 0.011). The adjusted-multivariable analysis for potential confounding variables did not show any association between the lipoproteins and dietary patterns (i.e., aMED and aHEI). In conclusion, none of the quantitative characteristics of lipoproteins were concomitantly associated with the extent of adherence to the Mediterranean diet measured using the aMED or aHEI scores in the studied population. Our findings also revealed that people with the highest adherence were older, had a higher body mass index (BMI) and more frequently had dyslipidemia, hypertension, or diabetes than those with the lowest adherence to the Mediterranean diet (MDiet). Thus, further research may be needed to assess the potential role of the dietary pattern on the ALP.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Impact of dietary lipids on the reverse cholesterol transport, What we learned from animal studies

  • Papotti, Bianca|||0000-0003-3916-7003
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Potì, Francesco|||0000-0002-1708-0719
  • Zanotti, Ilaria
Reverse cholesterol transport (RCT) is a physiological mechanism protecting cells from an excessive accumulation of cholesterol. When this process begins in vascular macrophages, it acquires antiatherogenic properties, as has been widely demonstrated in animal models. Dietary lipids, despite representing a fundamental source of energy and exerting multiple biological functions, may induce detrimental effects on cardiovascular health. In the present review we summarize the current knowledge on the mechanisms of action of the most relevant classes of dietary lipids, such as fatty acids, sterols and liposoluble vitamins, with effects on different steps of RCT. We also provide a critical analysis of data obtained from experimental models which can serve as a valuable tool to clarify the effects of dietary lipids on cardiovascular disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide protects against diet-induced body weight gain, increases energy expenditure, and induces white adipose tissue beiging

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Rodríguez-Millán, Elisabeth
  • Sebastián, David|||0000-0002-7260-3869
  • Blanco-Soto, Rosi
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Mato, Eugènia|||0000-0001-8121-9335
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Roglans, Núria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Villena, Josep A.|||0000-0002-2200-2985
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Scope: Interventions that boost NAD+ availability are of potential therapeutic interest for obesity treatment. The potential of nicotinamide (NAM), the amide form of vitamin B3 and a physiological precursor of nicotinamide adenine dinucleotide (NAD)+, in preventing weight gain has not previously been studied in vivo. Other NAD+ precursors have been shown to decrease weight gain; however, their impact on adipose tissue is not addressed. Methods and results: Two doses of NAM (high dose: 1% and low dose: 0.25%) are given by drinking water to C57BL/6J male mice, starting at the same time as the high-fat diet feeding. NAM supplementation protects against diet-induced obesity by augmenting global body energy expenditure in C57BL/6J male mice. The manipulation markedly alters adipose morphology and metabolism, particularly in inguinal (i) white adipose tissue (iWAT). An increased number of brown and beige adipocyte clusters, protein abundance of uncoupling protein 1 (UCP1), mitochondrial activity, adipose NAD+, and phosphorylated AMP-activated protein kinase (P-AMPK) levels are observed in the iWAT of treated mice. Notably, a significant improvement in hepatic steatosis, inflammation, and glucose tolerance is also observed in NAM high-dose treated mice. Conclusion: NAM influences whole-body energy expenditure by driving changes in the adipose phenotype. Thus, NAM is an attractive potential treatment for preventing obesity and associated complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Purpose of Review: We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH). Recent Findings: RCT from macrophages (m-RCT), a vascular cell type of major influence on atherosclerosis, is impaired in FH due to defective low-density lipoprotein receptor (LDLR) function via both the HDL- and LDL-mediated pathways. Potential mechanisms include impaired HDL metabolism, which is linked to increased LDL levels, as well as the increased transport of cellular unesterified cholesterol to LDL, which presents a defective catabolism. Summary: RCT dysfunction is consistently associated with mutation-positive FH linked to decreased HDL levels as well as impaired HDL remodeling and LDLR function. It remains to be explored whether these alterations are also present in less well-characterized forms of FH, such as cases with no identified mutations, and whether they are fully corrected by current standard treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subjects With Diabetes Mellitus Are at Increased Risk for Developing Tuberculosis, A Cohort Study in an Inner-City District of Barcelona (Spain)

  • Antonio-Arques, Violeta|||0000-0001-7467-0558
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Moreno-Martinez, A.
  • Real, J.
  • Orcau, Àngels|||0000-0001-8109-7614
  • Mauricio, Didac|||0000-0002-2868-0250
  • Mata-Cases, Manel|||0000-0003-3693-3622
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Navas, Elena|||0000-0001-5823-5847
  • Puig Treserra, Ramon|||0000-0003-1224-884X
  • Barrot de la Puente, Joan|||0000-0002-7482-7647
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Del Val García, José Luis|||0000-0002-0391-9368
  • Vlacho, Bogdan|||0000-0003-3768-8112
  • Caylà, Joan A.|||0000-0003-3891-111X
Background: Tuberculosis is the leading cause of mortality from lung infectious disease worldwide in recent years, and its incidence has re-emerged in large cities in low-incidence countries due to migration and socioeconomic deprivation causes. Diabetes mellitus and tuberculosis are syndemic diseases, with diabetes being considered a risk factor for developing tuberculosis. Objective: To investigate whether diabetic patients were at increased risk of tuberculosis living in an inner-district of a large city of northeastern Spain. Methods: Observational matched retrospective cohort study based on clinical records from the population of the lowest socioeconomic status in Barcelona (Ciutat Vella district). A cohort including patients with type 1 and type 2 diabetes mellitus in 2007 and new cases until 2016 (8004 subjects), matched 1:1 by sex and age with a non-diabetic cohort. Follow-up period was until December 31st 2018. We evaluated the risk of developing tuberculosis in diabetic patients compared to non-diabetic patients during the follow up period. We used time-to-event analysis to estimate the incidence of tuberculosis, and competing risks regression by clusters and conditional Cox regression models to calculate the hazard ratio (HR) and its 95% confidence intervals (CI). Results: Among the 16,008 included subjects, the median follow-up was 8.7 years. The mean age was 57.7 years; 61.2% men and 38.8% women in both groups. The incidence of tuberculosis was 69.9 per 100,000 person-years in diabetic patients, and 40.9 per 100,000 person-years in non-diabetic patients (HR = 1.90; CI: 1.18-3.07). After adjustment for the country of origin, chronic kidney disease, number of medical appointments, BMI, alcoholism and smoking, the risk remained higher in diabetic patients (1.66: CI 0.99-2.77). Additionally, subjects from Hindustan or with a history of alcohol abuse also showed a higher risk of developing tuberculosis (HR = 3.51; CI:1.87-6.57, and HR = 2.73; CI:1.22-6.12 respectively). Conclusion: People with diabetes mellitus were at higher risk of developing tuberculosis in a large cohort recruited in an inner-city district with a high incidence for this outcome, and low socioeconomic conditions and high proportion of migrants. This risk was higher among Hindustan born and alcohol abusers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of α-klotho with subclinical carotid atherosclerosis in subjects with type 1 diabetes mellitus

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Hernández García, Marta|||0000-0003-1237-298X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Ribes-Betriu, Aina
  • Real, Jordi|||0000-0002-5979-8948
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Rossell, Joana|||0000-0003-1500-6379
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Dusso, Adriana Silvia
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
Background: Compelling evidence suggests that the fibroblast growth factor 23 (FGF23) / α-klotho axis is impaired in subjects with diabetes mellitus. We examined the relationship between parameters related to calcium/phosphate homeostasis, including FGF23 and α-klotho, and subclinical carotid atherosclerosis burden in type 1 diabetes mellitus (T1D) subjects. Methods: This cross-sectional study involved 226 subjects with T1D and 147 age-, sex- and plaque-matched, non-diabetic (non-T1D) subjects, both with normal renal function. Carotid ultrasound was performed to determine the presence and burden of atheromatous plaques. Concentrations of the intact form of FGF23 and α-klotho were assessed by ELISA. Calcium, phosphate, parathyroid hormone, and vitamin D levels were also determined. Negative binomial regression models were used to examine relationship between parameters studied and subclinical carotid atherosclerosis. Results: Only FGF23 was increased in T1D compared with non-diabetic subjects (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport

  • Hueso, Miguel|||0000-0002-1824-9141
  • Griñán, Raquel|||0000-0002-9457-3365
  • Mallen, Adrián
  • Navarro, Estanislao
  • Purqueras, Elvira
  • Gomà-Gállego, Montserrat
  • Sbraga, Fabrizio
  • Blasco-Lucas, Arnau|||0000-0002-2796-7428
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Santos, David|||0000-0003-1157-4969
  • Canyelles, Marina|||0000-0002-0278-5337
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
Objective: To determine whether miR-125b regulates cholesterol efflux in vivo and in vitro through the regulation of scavenger receptor type B1 (SR-B1). Approach and results: We demonstrated that miR-125b is up-regulated in the human aortas of patients with CAD and is located in macrophages and vascular smooth muscle cells (VSMCs). We identified SCARB1 as a direct target of miR-125b by repressing the activity of the SCARB1 3'-untranslated region reporter construct. Moreover, the overexpression of miR-125b in both human and mouse macrophages as well as VSMCs was found to downregulated the expression of the SCARB1 and the SR-B1 protein levels, thereby impairing α-HDL-mediated macrophage cholesterol efflux in vitro. The in vivo reverse cholesterol transport (RCT) rate from non-cholesterol-loaded macrophages transfected with miR-125b to feces was also found to be decreased when compared with that of control mimic-transfected macrophages. Conclusions: Together, these results provide evidence that miR-125b downregulates SCARB1 and SR-B1 in both human and mouse macrophages as well as VSMCs, thereby impairing macrophage cholesterol efflux in vitro and the whole macrophage-specific RCT pathway in vivo.